Carbapenem Utilization in a Tertiary Referral Teaching Hospital Over 8 Years: A Quasi-Experimental Study
-
Maryam Taghizadeh-Ghehi
,
Fatemeh Farahani
,
Hassan Torkamandi
,
Mehrdad Assarian
,
Samira Chaibakhsh
,
Mohammad Reza Javadi
Abstract
Background: The high prevalence of resistance to broad-spectrum antibiotics in the hospital setting is a challenge worldwide. Inappropriate use of carbapenems has led to growing antimicrobial resistance, specifically in gram-negative pathogens. Evidence suggested that interventions might improve the appropriate use of carbapenems in hospitals. Therefore, we aimed to compare the appropriate use of carbapenems before and after guideline implementation and to investigate consumption trends over 8 years, following restriction policies.
Methods: This quasi-experimental study was conducted in a tertiary referral teaching hospital. Before and after the implementation of the carbapenem use guideline in the hospital, utilization of imipenem and meropenem was evaluated with respect to the appropriateness of indication, initial dose, maintenance dose, and obtaining cultures. Annual consumption of carbapenems in terms of Defined Daily Doses (DDDs) per 100 Occupied Bed-Days (OBDs) was estimated in the hospital from 2014 to 2021.
Results: The frequency of generally appropriate orders increased from 31.6% at baseline to 38% after the primary intervention (P=0.057). The number of cases with carbapenem use for more than 5 days without obtaining cultures decreased significantly in the second evaluation phase (from 15.8% to 8.1%, P=0.001). Despite fluctuations and a non-steady trend, carbapenem consumption increased from 39.30 to 71.37 DDDs/100 OBDs over 8 years with a statistically significant trend (p < 0.001, R² = 0.93).
Conclusion: The rising carbapenem consumption rate was slowed down following the interventions. Additionally, our study demonstrated that guideline implementation improved the appropriate choice of carbapenem and the timely obtaining of cultures. However, the practice change was temporary and limited before the commencement of the restriction policy and ASP. Prospective audit and feedback might be necessary to achieve sustainable changes in the appropriate use of carbapenem in hospitals.
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-655.
Davey P, Brown E, Charani E, Fenelon L, Gould IM, Holmes A, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2013;(4):CD003543.
Seah XFV, Ong YLR, Tan SW, Krishnaswamy G, Chong CY, Tan NWH, Thoon KC. Impact of an antimicrobial stewardship program on the use of carbapenems in a tertiary women's and children's hospital, Singapore. Pharmacotherapy. 2014;34(11):1141-1150.
Hulscher M, Prins JM. Antibiotic stewardship: does it work in hospital practice? A review of the evidence base. Clin Microbiol Infect. 2017;23(11):799-805.
Mahini S, Hayatshahi A, Torkamandi H, Gholami K, Javadi M. Carbapenem utilization in critically ill patients. J Pharm Care. 2013;1(4):141-144.
Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis. 2024;403.
Apisarnthanarak A, Mundy LM. Inappropriate use of carbapenems in Thailand: a need for better education on de-escalation therapy. Clin Infect Dis. 2008;47(6):858-859.
Farsad BF, Hadavand N, Salehi H, Shekari F. Carbapenems, linezolid, teicoplanin utilization evaluation in a large teaching based hospital (Shahid Rajaie Heart Center, Tehran): a quality improvement study. Biomed Pharmacol J. 2016;9(2):525-532.
Mahini S, Hayatshahi A, Torkamandi H, Gholami K, Javadi M. Carbapenem utilization in critically ill patients. J Pharm Care. 2015;1(4):141-144.
Michalski D, Ghamrawi RJ, Tsigrelis C. Evaluation of institutional guideline adherence for carbapenem use at a large academic medical center. Infect Dis (Lond). 2018;50(3):226-228.
Van Hollebeke M, Chapuis C, Bernard S, Foroni L, Stahl JP, Bedouch P, Pavese P. Compliance with carbapenem guidelines in a university hospital. Med Mal Infect. 2016;46(2):72-78.
Yoon D, Koo HL, Choe PG, Song K-H, Park WB, Bang JH, et al. The purpose and appropriateness of carbapenem use in a single university hospital, 2009–2013. Expert Rev Clin Pharmacol. 2016;9(6):863-865.
Voor in 't holt AF, Severin JA, Lesaffre EMEH, Vos MC. A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2014;58(5):2626-2637.
Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17(10):1791-1798.
Sistanizad M, Kouchek M, Miri M, Goharani R, Solouki M, Ayazkhoo L, et al. Carbapenem restriction and its effect on bacterial resistance in an intensive care unit of a teaching hospital. Iran J Pharm Res. 2013;12(3):503-509.
de With K, Allerberger F, Amann S, Apfalter P, Brodt H-R, Eckmanns T, et al. Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases. Infection. 2016;44(3):395-439.
Kirk A, Pierce J, Doll M, Lee K, Pakyz A, Kim J, et al. Effect of carbapenem restriction on prescribing trends for immunocompromised wards at an academic medical center. Am J Infect Control. 2019;47(7):813-818.
Pakyz AL, Oinonen M, Polk RE. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53(5):1983-1986.
Robson SE, Cockburn A, Sneddon J, Mohana A, Bennie M, Mullen AB, et al. Optimizing carbapenem use through a national quality improvement programme. J Antimicrob Chemother. 2018;73(8):2223-2230.
Seah VXF, Ong RYL, Lim ASY, Chong CY, Tan NWH, Thoon KC. Impact of a carbapenem antimicrobial stewardship program on patient outcomes. Antimicrob Agents Chemother. 2017;61(9):e00736-17.
Teng CB, Ng TM, Tan MW, Tan SH, Tay M, Lim SF, et al. Safety and effectiveness of improving carbapenem use via prospective review and feedback in a multidisciplinary antimicrobial stewardship programme. Ann Acad Med Singap. 2015;44(1):19-25.
Wanla W, Katip W, Supakul S, Apiwatnakorn P, Khamsarn S. Effects of an antimicrobial restriction system on appropriate carbapenem use in a hospital without infectious diseases consultation. Int J Gen Med. 2017;10:443-449.
Janssen J, Kinkade A, Man D. Carbapenem utilization evaluation in a large community hospital (CARBON): a quality improvement study. Can J Hosp Pharm. 2015;68(4):327-331.
Hajiabdolbaghi M, Makarem J, Salehi M, Dehghan Manshadi SA, Mohammadnejad E, et al. Does an antimicrobial stewardship program for carbapenem use reduce costs? An observation in Tehran, Iran. Caspian J Intern Med. 2020;11(3):329-332. doi:10.22088/cjim.11.3.329.
Vahidi G, Mohammadi M, Shojaei L, Ramezani M, Jafari S, Khalili H. Antibiotic stewardship program in intensive care unit: first report from Iran. Int J Crit Illn Inj Sci. 2018;8(2):83-89.
Hasanzadeh S, Mehri A, Manouchehri M, Ganjloo S, Shahabifar MS, Ghazvini K. A report of antibiotic restriction policy in Ghaem university hospital, Mashhad, Northeast Iran. Clin Epidemiol Glob Health. 2020;8(4):1345-1347.
Bahrampour Juybari K, Vosooghi V, Zahmatkesh M, Mirmohammadkhani M, Paknazar F. Compliance of imipenem and meropenem administration with the national antimicrobial stewardship program in a referral teaching hospital in Iran. Hosp Pract (1995). 2022;50(1):49-54.
Laki B, Taghizadeh-Ghehi M, Assarian M, Heidari K, Torkamandi H, Javadi MR, Gholami K. Effect of hospital-wide interventions to optimize albumin use in a tertiary hospital. J Clin Pharm Ther. 2017;42(6):704-9.
Schwartz DN, Abiad H, DeMarais PL, Armeanu E, Trick WE, Wang Y, Weinstein RA. An educational intervention to improve antimicrobial use in a hospital-based long-term care facility. J Am Geriatr Soc. 2007;55(8):1236-1242.
Ali M, Kalima P, Maxwell S. Failure to implement hospital antimicrobial prescribing guidelines: a comparison of two UK academic centres. J Antimicrob Chemother. 2006;57(5):959-962.
Macfarlane J. Community-acquired pneumonia. Br J Dis Chest. 1987;81(2):116-127.
Chang Y-Y, Chen H-P, Lin C-W, Tang J-J, Hsu T-Y, Weng Y-C, et al. Implementation and outcomes of an antimicrobial stewardship program: effectiveness of education. J Chin Med Assoc. 2017;80(6):353-359.
Giovannenze F, Del Vecchio P, Frondizi F, Rando E, Leanza GM, Gross MM, et al. Effect of an educational antimicrobial stewardship programme on antibiotic prescriptions' appropriateness in three medical units of a large university hospital: an interrupted time series analysis. J Hosp Infect. 2025;162:127-135.
Hadi U, Kolopaking EP, Gardjito W, Gyssens IC, Van den Broek P. Antimicrobial resistance and antibiotic use in low-income and developing countries. Folia Med Indones. 2006;42(3):183-195.
Kollef M, Niederman M. Antimicrobial resistance in the ICU: the time for action is now. Crit Care Med. 2001;29(4 Suppl):N1-N2.
Rodloff A, Goldstein E, Torres A. Two decades of imipenem therapy. J Antimicrob Chemother. 2006;58(5):916-929.
| Files | ||
| Issue | Vol 13, No 4 (Autumn 2025) | |
| Section | Original Article(s) | |
| Keywords | ||
| Carbapenem Antimicrobial Stewardship Program Drug Utilization Evaluation Antimicrobial Resistance Clinical Pharmacy | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
